

Application of : Angelo CECI et al) Art Unit: 1624 U.S. Appln. No. : 10/699,374) Examiner: Kahsay Habte

Confirmation No.: 3053

U.S. Filing Date: October 31, 2003

Title of Invention: Positive Allosteric AMPA Receptor Modulators (PAARM), Processes

for Preparing Them, and Their Use as Pharmaceutical Compositions

Attny. Docket No.: 1/1210-1-C1

Mail Stop RCE Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

September 15, 2005

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

21. ·
Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.
1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.
1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:
A statement as specified in 37 C.F.R. §1.97(e) [see below]; or
The fee set forth in 37 C.F.R. §1.17(p).

The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
☐ 1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Mary-Eilen M. Devlin Attorney for Applicant(s)

Reg. No. 27,928

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 798-4866

Date: September 15, 2005

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:

Mail Stop RCE

Commissioner For Patents

P. O. Box 1450

Alexandria, VA 22313-1450

on September 15, 2005.

Mary-Ellen M. Devlin, Reg. No. 27,928



PTC/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 1449A/PTO	titute for form 1449A/PTO			mplete if Known
				Application Number	10/699,374
	INFORMATION DI	SCLC	SURE	Filing Date	October 31, 2003
	· · · · · · · · · · · · · · · · · · ·	Application Number 10/699,374	First Named Inventor	Angelo CECI et al	
	OIXILIILIII DI				
	(Use as many sheets as	s necessary)	Examiner Name	K. Habte
Shee	t 1	of	2	Attorney Docket Number	1/1210-1-C1

			U. S. PATENT		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (4 known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 2002/013313 A1	01/31/2002	Karin Winter, et al.	
		^{US-} 6,083,947 A	07/04/2000	Granger & Lynch	
		US-			
·		US-			
		US-			***************************************
		US-			

		FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ 'Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 99/67242	12/29/1999	Merck & Co. Inc.		
*						
	Ī					

Examiner	Date		
Signature	Considered	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspio.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Traiscallor is audicided.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Signature

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete If Known **Application Number** 10/699.374 Filing Date INFORMATION DISCLOSURE October 31, 2003 First Named Inventor STATEMENT BY APPLICANT Angelo CECI et al Art Unit 1624 (Use as many sheets as necessary) Examiner Name K. Habte Attorney Docket Number | 1/1210-1-C1 Sheet of 2 2

			_	
NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
		R.R. WILKENING, et al., Synthesis and Activity of 2-(Sulfonamido)Methyl-Carbapenems: Discovery of a Novel, Anti-MRSA1,8-Naphthosultam Pharmacopore, Bioorganic & Medicinal Chemistry Letters 9, (1999) pp 673-678, Oxford, GB, Example 16; table 1.		
			····	
			••••	
***************************************			••••	
***************************************			••••	
			••••	
***************************************	• • • • • • • • • • • • • • • • • • • •		••••	

Examiner		Date		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.